BiotechTube
GT Apeiron

GT Apeiron

Burlingame, United States
apeiron-bio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Apeiron Therapeutics is a clinical-stage biotech company at the intersection of artificial intelligence and oncology drug discovery. Its core strategy involves using an AI-driven, structure-based design platform to develop targeted small molecule therapies for cancers with high unmet need, as evidenced by its lead program GTA182 already in Phase 1 trials. The company benefits from a leadership team with deep expertise in drug discovery, immuno-oncology, and cross-border biotech operations between the U.S. and China. Apeiron's approach aims to accelerate the identification and development of precision oncology drugs.

Oncology

Technology Platform

Structure-based, AI-driven drug design platform for small molecule discovery and optimization.

Opportunities

The significant unmet need in biomarker-defined cancers, such as MTAP-deleted tumors, presents a clear precision medicine opportunity.
Validating its AI platform with clinical success could enable rapid, low-cost generation of a sustainable pipeline, creating immense platform value and partnership potential.

Risk Factors

High clinical development risk as lead asset is only in Phase 1.
Heavy reliance on an unproven (in terms of clinical output) AI/ML platform introduces technology execution risk.
The cross-border operational model adds regulatory, cultural, and geopolitical complexity.

Competitive Landscape

Apeiron competes in the highly crowded precision oncology and AI-driven drug discovery spaces. It faces competition from large pharma with internal AI efforts, well-funded pure-play AI biotechs (e.g., Recursion, Exscientia), and numerous biotechs targeting MTAP and related synthetic lethality pathways.

More companies in AI / Machine Learning →More companies in United States →